On November 2, 2020 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, reported that it will release its financial results for the third quarter of 2020 on Wednesday, November 18, 2020 (Press release, Evogene, NOV 2, 2020, View Source [SID1234569735]). Dr. Elran Haber, CEO of Evogene’s human microbiome subsidiary, Biomica Ltd., will join the conference call to discuss Biomica’s activity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.

A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5901 internationally. The replay will be accessible through November 20, 2020, and an archive of the webcast will be available on the Company’s website for the following 30 days.

On November 2, 2020 Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, reported it expects to release its third quarter 2020 financial results before markets open on Monday, November 16, 2020 (Press release, Nuvo Pharmaceuticals, NOV 2, 2020, View Source [SID1234569733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will subsequently hold a conference call the same day, Monday, November 16, 2020 at 8:30 a.m. ET, hosted by Jesse Ledger, Nuvo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

View Source;tp_key=8417e4c6b2

An archived replay of the webcast will be available by clicking the link above.

On November 2, 2020 Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, reported the U.S. Food and Drug Administration (FDA) has lifted a clinical hold on the Company’s Phase 1 study of P-PSMA-101 in metastatic castration-resistant prostate cancer (mCRPC) and plans to resume the trial immediately (Press release, Poseida Therapeutics, NOV 2, 2020, View Source [SID1234569732]). P-PSMA-101 is the company’s first solid tumor autologous CAR-T therapeutic candidate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has agreed to implement protocol amendments intended to increase patient compliance and safety that include modified inclusion and exclusion criteria and frequency of monitoring and laboratory testing.

About P-PSMA-101
P-PSMA-101 is an autologous CAR-T therapeutic candidate in metastatic castration-resistant prostate cancer (mCRPC). It is designed to target prostate-specific membrane antigen (PSMA), which is expressed on mCRPC cells. It was developed using Poseida’s proprietary piggyBac DNA Modification System, which produces product candidates with a high percentage of stem cell memory T (TSCM) cells. A Phase 1 trial of P-PSMA-101 in mCRPC was initiated in May 2020.

On November 2, 2020 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will present at the following virtual investor conferences (Press release, Insmed, NOV 2, 2020, View Source [SID1234569731]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020 at 3:30 p.m. ET

The Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 10:00 a.m. ET
Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.

On November 2, 2020 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that it will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020, after the close of the U.S. financial markets (Press release, Arena Pharmaceuticals, NOV 2, 2020, View Source [SID1234569730]). The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please join the conference call at least 20 minutes early to register. You can access the live webcast under the investor relations section of Arena’s website. A replay of the event will be archived for 30 days after the call.